The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
Open accessAbstract
Purpose: Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated with life-threatening complications. Most deaths occur within the first 2 years after transplantation. In this report, we examine long-term survival in 2-year survivors in the largest cohort ever studied. Patients and Methods: Records of 10,632 patients worldwide reported to the Center for International Blood and Marrow Transplant Research who were alive and disease free 2 years after receiving a myeloablative allogeneic HCT before 2004 for acute myelogenous or lymphoblastic leukemia, myelodysplastic syndrome, lymphoma, or severe aplastic anemia were reviewed. Results: Median follow-up was 9 years, and 3,788 patients had been observed for 10 or more years. The probability of being alive 10 years after HCT was 85%. The chief risk factors for late death included older age and chronic graft-versus-host disease (GVHD). For patients who underwent transplantation for malignancy, relapse was the most common cause of death. The greatest risk factor for late relapse was advanced disease at transplantation. Principal risk factors for nonrelapse deaths were older age and GVHD. When compared with age, sex, and nationality-matched general population, late deaths remained higher than expected for each disease, with the possible exception of lymphoma, although the relative risk generally receded over time. Conclusion: The prospect for long-term survival is excellent for 2-year survivors of allogeneic HCT. However, life expectancy remains lower than expected. Performance of HCT earlier in the course of disease, control of GVHD, enhancement of immune reconstitution, less toxic regimens, and prevention and early treatment of late complications are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival Analysis, Techniques for Censored and Truncated Data
Rao, M. B. (1998) · Technometrics · doi:10.1080/00401706.1998.10485206 · Cited by 3,617
Survival Analysis: Techniques for Censored and Truncated Data
Klein, J. P., & Moeschberger, M. L. (2003) · Statistics for Biology and Health · doi:10.1007/b97377 · Cited by 1,816
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Self-citationSolid Cancers after Bone Marrow Transplantation
Curtis, R. E., Rowlings, P. A., Deeg, H. J., Shriner, D. A., Socié, G., Travis, L. B., Horowitz, M. M., Witherspoon, R. P., Hoover, R. N., Sobocinski, K. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361301 · Cited by 965
Self-citationMertens, A. C., Liu, Q., Neglia, J. P., Wasilewski, K., Leisenring, W., Armstrong, G. T., Robison, L. L., & Yasui, Y. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn310 · Cited by 730
Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation
Socié, G., Stone, J. V., Wingard, J. R., Weisdorf, D., Henslee-Downey, P. J., Bredeson, C., Cahn, J.-Y., Passweg, J. R., Rowlings, P. A., Schouten, H. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410103 · Cited by 698
Self-citationBhatia, S., Francisco, L., Carter, A., Sun, C.-L., Baker, K. S., Gurney, J. G., McGlave, P. B., Nademanee, A., O'Donnell, M., Ramsay, N. K. C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082933 · Cited by 540
Majhail, Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120032 · Cited by 509
Solid cancers after allogeneic hematopoietic cell transplantation
Rizzo, J. D., Curtis, R. E., Socié, G., Sobocinski, K. A., Gilbert, E., Landgren, O., Travis, L. B., Travis, W. D., Flowers, M. E. D., Friedman, D. L., et al. (2009) · Blood · doi:10.1182/blood-2008-05-158782 · Cited by 439
Self-citationQuantification of the completeness of follow-up
Clark, T. G., Altman, D. G., & Stavola, B. L. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08272-7 · Cited by 406
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Landgren, O., Gilbert, E. S., Rizzo, J. D., Socié, G., Banks, P. M., Sobocinski, K. A., Horowitz, M. M., Jaffe, E. S., Kingma, D. W., Travis, L. B., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178046 · Cited by 400
Self-citationLife Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation
Martin, P. J., Counts, G. W., Appelbaum, F. R., Lee, S. J., Sanders, J. E., Deeg, H. J., Flowers, M. E. D., Syrjala, K. L., Hansen, J. A., Storb, R. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6693 · Cited by 366
Solid Cancers After Bone Marrow Transplantation
Bhatia, S., Louie, A. D., Bhatia, R., O’Donnell, M. R., Fung, H., Kashyap, A., Krishnan, A., Molina, A., Nademanee, A., Niland, J. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.464 · Cited by 316
Rizzo, J. D., Wingard, J. R., Tichelli, A., Lee, S. J., Van Lint, M. T., Burns, L. J., Davies, S. M., Ferrara, J. L. M., & Socié, G. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.012 · Cited by 302
Self-citationKrishnan, A., Bhatia, S., Slovak, M. L., Arber, D. A., Niland, J. C., Nademanee, A., Fung, H., Bhatia, R., Kashyap, A., Molina, A., et al. (2000) · Blood · doi:10.1182/blood.v95.5.1588.005k38_1588_1593 · Cited by 285
Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation
Duell, T., van Lint, M. T., Ljungman, P., Tichelli, A., Socie, G., Apperley, J. F., Weiss, M., Cohen, A., Nekolla, E., & Kolb, H.-J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-3-199702010-00002 · Cited by 228
Long-Term Outcome After Marrow Transplantation for Severe Aplastic Anemia
Deeg, H. J., Leisenring, W. M., Storb, R. F., Nims, J. W., Flowers, M. E. D., Witherspoon, R. P., Sanders, J. E., & Sullivan, K. M. (1998) · Blood · doi:10.1182/blood.v91.10.3637 · Cited by 202
Metayer, C. (2003) · Blood · doi:10.1182/blood-2002-04-1261 · Cited by 201
Weisdorf, D., Spellman, S., Haagenson, M., Horowitz, M., Lee, S., Anasetti, C., Setterholm, M., Drexler, R., Maiers, M., King, R., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.04.003 · Cited by 197
Self-citationA Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial
Copelan, E. A., Casper, J. T., Carter, S. L., van Burik, J. H., Hurd, D. D., Mendizabal, A. M., Wagner, J. E., Yanovich, S., & Kernan, N. A. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.08.047 · Cited by 154
Goldman, J. M., Majhail, N. S., Klein, J. P., Wang, Z., Sobocinski, K. A., Arora, M., Horowitz, M. M., & Rizzo, J. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7757 · Cited by 137
Self-citationSimple Parametric and Nonparametric Models for Excess and Relative Mortality
Andersen, P. K., & Væth, M. (1989) · Biometrics · doi:10.2307/2531494 · Cited by 116
MacArthur, A. C., Spinelli, J. J., Rogers, P. C., Goddard, K., Abanto, Z. U., & McBride, M. L. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20922 · Cited by 74
Bishop, M. M., Lee, S. J., Beaumont, J. L., Andrykowski, M. A., Rizzo, J. D., Sobocinski, K. A., & Wingard, J. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.09.015 · Cited by 73
Self-citationMajhail, N. S., Bajorunaite, R., Lazarus, H. M., Wang, Z., Klein, J. P., Zhang, M., & Rizzo, J. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07798.x · Cited by 61
Self-citationPond, G. R., Lipton, J. H., & Messner, H. A. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.518 · Cited by 50
Cited by
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
Self-citationHanash, A. M., Dudakov, J. A., Hua, G., O’Connor, M. H., Young, L. F., Singer, N. V., West, M. L., Jenq, R. R., Holland, A. M., Kappel, L. W., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.028 · Cited by 584
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger, N., Solano, C., Wolschke, C., Bandini, G., Patriarca, F., Pini, M., Nagler, A., Selleri, C., Risitano, A., Messina, G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506002 · Cited by 573
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Zeiser, R., Polverelli, N., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033122 · Cited by 527
Majhail, Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120032 · Cited by 509
Metadata
- Authors
- Wingard, J. R., Majhail, N. S., Brazauskas, R., Wang, Z., Sobocinski, K. A., Jacobsohn, D., Sorror, M. L., Horowitz, M. M., Bolwell, B., Rizzo, J. D., & Socié, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-06-01
- Volume
- 29
- Issue
- 16
- Pages
- 2230-2239
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171841416
- Cited by
- 632
- References
- 27
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.